Gemcitabine in combination with chemotherapy in the treatment of recurrent or metastatic breast cancer

Abstract

Abstract:Gemcitabine based chemotherapy is effective in recurrent or metastatic breast cancer. Besides the 3 week regimen in combination with paclitaxel, individualized treatments are also applied to combine gemcitabine with other agents such as docetaxel or platinum, or to administer by different frequency or dose, or to continuously maintain on the treatment as an extension to front line. It is demonstrated that gemcitabine in combination with taxanes can obtain survival benefit, largely in patients with visceral metastasis or hormone receptor negative. Initial evidence has also supported the feasibility of continuous maintenance. Finally, gemcitabine in combination with cisplatin is a better option for the metastatic triple negative breast cancer.

Key words:Breast neoplasms,Drug therapy,Gemcitabine

Tong Zhongsheng, Xu Cong, Wang Jin. Gemcitabine in combination with chemotherapy in the treatment of recurrent or metastatic breast cancer[J]. Journal of International Oncology, 2015, 42(10): 769-772.

References

［1］ Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010［J］. Chin J Cancer Res, 2014, 26(1): 48-58. ［2］ O′Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer［J］. Oncologist, 2005, 10 Suppl 3: 20-29. ［3］ Ferrazzi E, Stievano L. Gemcitabine: monochemotherapy of breast cancer［J］. Ann Oncol, 2006, 17 Suppl 5: v169-172. ［4］ Zupi G, Scarsella M, D′Angelo C, et al. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells ［J］. Cancer Biol Ther, 2005, 4(8): 866-871. ［5］ Ricotti L, Tesei A, De Paola F, et al. In vitro scheduledependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines［J］. Clin Cancer Res, 2003, 9(2): 900-905. ［6］ Albain KS, Nag SM, CalderilloRuiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment［J］. J Clin Oncol, 2008, 26(24): 3950-3957. ［7］ Moinpour C, Wu J, Donaldson G, et al. Gemcitabine plus paclitaxel (GT) vs paclitaxel (T) as firstline therapy for anthracycline pretreated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase Ⅲ study ［C］. J Clin Oncol, 2004, 22(14S):621. ［8］ Xu B, Shen Z, Jiang Z, et al. A phase Ⅱ study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment［J］. Asia Pac J Clin Oncol, 2010, 6(4): 320-329. ［9］ Xu B, Zhang XQ, Chi HD, et al. Consistent efficacy and safety of gemcitabinepaclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies［J］. Asia Pac J Clin Oncol, 2014, 10(4): 330-339. ［10］ Park YH, Jung KH, Im SA, et al. Phase Ⅲ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as firstline chemotherapy: KCSGBR0702［J］. J Clin Oncol, 2013, 31(14): 1732-1739. ［11］ Colomer R, LlombartCussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase Ⅱ trial and predictive value of HER2 extracellular domain［J］. Ann Oncol, 2004, 15(2): 201-206. ［12］ Xu B, Jiang Z, Kim SB, et al. Biweekly gemcitabinepaclitaxel, gemcitabinecarboplatin, or gemcitabinecisplatin as firstline treatment in metastatic breast cancer after anthracycline failure: a phase Ⅱ randomized selection trial［J］. Breast Cancer, 2011, 18(3): 203-212. ［13］ Seidman AD, Berry D, Cirrincione C, et al. Randomized phase Ⅲ trial of weekly compared with every3weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840［J］. J Clin Oncol, 2008, 26 (10): 1642-1649. ［14］ Del Mastro L, Fabi A, Mansutti M, et al. Randomized phase 3 openlabel trial of firstline treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments［J］. BMC Cancer, 2013, 13: 164-174. ［15］ Chan S, Romieu G, Huober J, et al. Phase Ⅲ study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracyclinepretreated patients with metastatic breast cancer［J］. J Clin Oncol, 2009, 27(11): 1753-1760. ［16］ Seidman AD, Brufsky A, Ansari RH, et al. Phase Ⅲ trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer［J］. Ann Oncol, 2011, 22(5): 1094-1101. ［17］ Karachaliou N, Kouroussis Ch, Papakotoulas P, et al. A multicenter phase Ⅱ trial of docetaxel plus gemcitabine as salvage treatment in anthracycline and taxanepretreated patients with metastatic breast cancer［J］. Cancer Chemother Pharmacol, 2012, 69(5): 1345-1352. ［18］ Murialdo R, Bertolotti F, Pastorino G, et al. Biweekly docetaxel and gemcitabine regimen in her2negative and anthracyclinepretreated metastatic breast cancer patients: a multicenter phase Ⅱ trial［J］. Cancer Chemother Pharmacol, 2011, 68(4): 1009-1016. ［19］ Pelegrí A, Calvo L, Antón A, et al. Docetaxel/gemcitabine administered every other week as firstline treatment for metastatic breast cancer: final results of a phase Ⅱ trial［J］. Clin Breast Cancer, 2005, 6(5): 433-438. ［20］ Papadimitriou CA, Kalofonos H, Zagouri F, et al. Weekly docetaxel with or without gemcitabine as secondline chemotherapy in paclitaxelpretreated patients with metastatic breast cancer: a randomized phase Ⅱ study conducted by the Hellenic CoOperative Oncology Group［J］. Oncology, 2009, 77(34): 212-216. ［21］ O′Shaughnessy JA, Pluenneke R, Sternberg J, et al. Phase Ⅱ trial of weekly docetaxel/gemcitabine as firstline chemotherapy in patients with locally recurrent or metastatic breast cancer［J］. Clin Breast Cancer, 2006, 6(6): 505-510. ［22］ Palmeri S, Vaglica M, Spada S, et al. Weekly docetaxel and gemcitabine as firstline treatment for metastatic breast cancer: results of a multicenter phase Ⅱ study ［J］. Oncology, 2005, 68(46): 438-445. ［23］ Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as firstline therapy for metastatic triplenegative breast cancer (CBCSG006): a randomized, openlabel, multicenter, phase 3 trial［J］. Lancet Oncol, 2015, 16(4): 436-446. ［24］ Ciruelos EM, Cortés J, CortésFunes H, et al. Gemcitabine and capecitabine in previously anthracyclinetreated metastatic breast cancer: a multicenter phase Ⅱ study (SOLTI 0301 trial)［J］. Ann Oncol, 2010, 21(7): 1442-1447. ［25］ Aapro MS, Martin C, Hatty S. Gemcitabine—a safety review［J］. Anticancer Drugs, 1998, 9(3): 191-201. ［26］ Ho MY, Mackey JR. Presentation and management of docetaxelrelated adverse effects in patients with breast cancer［J］. Cancer Manag Res, 2014, 6: 253-259. ［27］ Hartmann JT, Lipp HP. Toxicity of platinum compounds［J］. Expert Opin Pharmacother, 2003, 4(6): 889-901.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[6]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[9]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[10]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[11]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[12]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[13]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.
[15]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.